Characteristics of patients aged 20 years and older
. | No. eval . | Japanese . | No. eval . | White American . | No. eval . | African American . | No. eval . | Scandinavian . | No. eval . | Irish . | P . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease type, no. (%) | 562 | < .001 | |||||||||
| AML | 179 (32) | 829 | 256 (31) | 71 | 18 (26) | 192 | 72 (37) | 95 | 35 (37) | ||
| ALL | 136 (24) | 88 (11) | 1 (1) | 26 (14) | 17 (18) | ||||||
| CML | 247 (44) | 485 (58) | 52 (73) | 94 (49) | 43 (45) | ||||||
| Donor-patient sex match, no (%) | 521 | .39 | |||||||||
| M-M | 170 (33) | 828 | 232 (28) | 71 | 25 (35) | 191 | 69 (36) | 95 | 30 (32) | ||
| M-F | 117 (22) | 198 (24) | 14 (20) | 45 (24) | 27 (28) | ||||||
| F-M | 137 (26) | 221 (27) | 17 (24) | 37 (19) | 24 (25) | ||||||
| F-F | 97 (19) | 177 (21) | 15 (21) | 40 (21) | 14 (15) | ||||||
| Donor-patient CMV status, no (%) | 562 | < .001 | |||||||||
| Both negative | 40 (7) | 829 | 236 (28) | 71 | 5 (7) | 192 | 27 (14) | 95 | 53 (56) | ||
| At least 1 positive | 296 (53) | 561 (68) | 65 (92) | 160 (83) | 40 (42) | ||||||
| Inconclusive/unknown | 226 (40) | 32 (4) | 1 (1) | 5 (3) | 2 (2) | ||||||
| Conditioning regimen, no (%) | 562 | < .001 | |||||||||
| BuCy ± other | 244 (43) | 829 | 376 (45) | 1 | 41 (58) | 192 | 53 (28) | 95 | 53 (56) | ||
| TBICy ± other | 250 (45) | 238 (29) | 21 (29) | 122 (64) | 40 (42) | ||||||
| TBI ± other | 50 (9) | 124 (15) | 4 (6) | 4 (2) | 0 | ||||||
| Other | 18 (3) | 91 (11) | 5 (7) | 13 (8) | 2 (2) | ||||||
| Patient age, y, median (range) | 562 | 36 (20-59) | 829 | 40 (20-63) | 71 | 39 (21-60) | 192 | 41 (20-59) | 95 | 36 (20-56) | < .001 |
| 21-40 | 354 (63) | 406 (49) | 40 (56) | 89 (46) | 59 (62) | < .001 | |||||
| Older than 40 | 208 (37) | 423 (51) | 31 (44) | 103 (54) | 36 (38) | NA | |||||
| WBC count at diagnosis, × 109/L | 477 | 29 (0-965) | 790 | 58 (0-900) | 70 | 74 (1-516) | 186 | 40 (0-500) | 89 | 50 (1-547) | < .001 |
| Karnofsky score, 90%-100%, no. (%) | ND | 823 | 597 (73) | 71 | 61 (86) | 191 | 155 (81) | 93 | 57 (61) | .003 | |
| Year of treatment, mo, median (range) | 562 | 95 (90-99) | 829 | 94 (90-99) | 71 | 94 (90-99) | 192 | 93 (90-99) | 95 | 96 (90-99) | < .001 |
| NA | |||||||||||
| 1990-1994 | 258 (46) | 455 (55) | 40 (56) | 126 (66) | 40 (42) | < .001 | |||||
| 1995-1999 | 304 (54) | 374 (45) | 31 (44) | 66 (34) | 55 (58) | ||||||
| Time from diagnosis to treatment, mo, median (range) | 550 | 7.3 (0.2-69) | 829 | 5.0 (1.3-224) | 71 | 7.3 (2.1-89) | 190 | 6.0 (2.3-48) | 94 | 10.4 (4.7-94) | < .001 |
| Follow-up time among patients who survived, mo, median (range) | 372 | 65 (5-130) | 530 | 48 (2-138) | 42 | 33 (3-123) | 135 | 60 (4-120) | 66 | 42 (3-114) | < .001 |
. | No. eval . | Japanese . | No. eval . | White American . | No. eval . | African American . | No. eval . | Scandinavian . | No. eval . | Irish . | P . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Disease type, no. (%) | 562 | < .001 | |||||||||
| AML | 179 (32) | 829 | 256 (31) | 71 | 18 (26) | 192 | 72 (37) | 95 | 35 (37) | ||
| ALL | 136 (24) | 88 (11) | 1 (1) | 26 (14) | 17 (18) | ||||||
| CML | 247 (44) | 485 (58) | 52 (73) | 94 (49) | 43 (45) | ||||||
| Donor-patient sex match, no (%) | 521 | .39 | |||||||||
| M-M | 170 (33) | 828 | 232 (28) | 71 | 25 (35) | 191 | 69 (36) | 95 | 30 (32) | ||
| M-F | 117 (22) | 198 (24) | 14 (20) | 45 (24) | 27 (28) | ||||||
| F-M | 137 (26) | 221 (27) | 17 (24) | 37 (19) | 24 (25) | ||||||
| F-F | 97 (19) | 177 (21) | 15 (21) | 40 (21) | 14 (15) | ||||||
| Donor-patient CMV status, no (%) | 562 | < .001 | |||||||||
| Both negative | 40 (7) | 829 | 236 (28) | 71 | 5 (7) | 192 | 27 (14) | 95 | 53 (56) | ||
| At least 1 positive | 296 (53) | 561 (68) | 65 (92) | 160 (83) | 40 (42) | ||||||
| Inconclusive/unknown | 226 (40) | 32 (4) | 1 (1) | 5 (3) | 2 (2) | ||||||
| Conditioning regimen, no (%) | 562 | < .001 | |||||||||
| BuCy ± other | 244 (43) | 829 | 376 (45) | 1 | 41 (58) | 192 | 53 (28) | 95 | 53 (56) | ||
| TBICy ± other | 250 (45) | 238 (29) | 21 (29) | 122 (64) | 40 (42) | ||||||
| TBI ± other | 50 (9) | 124 (15) | 4 (6) | 4 (2) | 0 | ||||||
| Other | 18 (3) | 91 (11) | 5 (7) | 13 (8) | 2 (2) | ||||||
| Patient age, y, median (range) | 562 | 36 (20-59) | 829 | 40 (20-63) | 71 | 39 (21-60) | 192 | 41 (20-59) | 95 | 36 (20-56) | < .001 |
| 21-40 | 354 (63) | 406 (49) | 40 (56) | 89 (46) | 59 (62) | < .001 | |||||
| Older than 40 | 208 (37) | 423 (51) | 31 (44) | 103 (54) | 36 (38) | NA | |||||
| WBC count at diagnosis, × 109/L | 477 | 29 (0-965) | 790 | 58 (0-900) | 70 | 74 (1-516) | 186 | 40 (0-500) | 89 | 50 (1-547) | < .001 |
| Karnofsky score, 90%-100%, no. (%) | ND | 823 | 597 (73) | 71 | 61 (86) | 191 | 155 (81) | 93 | 57 (61) | .003 | |
| Year of treatment, mo, median (range) | 562 | 95 (90-99) | 829 | 94 (90-99) | 71 | 94 (90-99) | 192 | 93 (90-99) | 95 | 96 (90-99) | < .001 |
| NA | |||||||||||
| 1990-1994 | 258 (46) | 455 (55) | 40 (56) | 126 (66) | 40 (42) | < .001 | |||||
| 1995-1999 | 304 (54) | 374 (45) | 31 (44) | 66 (34) | 55 (58) | ||||||
| Time from diagnosis to treatment, mo, median (range) | 550 | 7.3 (0.2-69) | 829 | 5.0 (1.3-224) | 71 | 7.3 (2.1-89) | 190 | 6.0 (2.3-48) | 94 | 10.4 (4.7-94) | < .001 |
| Follow-up time among patients who survived, mo, median (range) | 372 | 65 (5-130) | 530 | 48 (2-138) | 42 | 33 (3-123) | 135 | 60 (4-120) | 66 | 42 (3-114) | < .001 |
Eval indicates evaluated; M, male; F, female; NA, not applicable; and ND, not done.